Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
The enrolled head and neck squamous cell carcinoma patients in this study received high-dose multiday chemotherapy with cisplatin and synchronous radiation therapy, which had a high risk of nausea and vomiting. On the first and third days, they took Netopitam Palonosetron capsules and dexamethasone to reduce the incidence of acute vomiting. The aim of this study is to evaluate the antiemetic effect of Netopitam Palonosetron capsules and to explore the effectiveness of using Netopitam Palonosetron capsules again for antiemetic treatment during the study period when breakthrough vomiting occurs.

Official Title
-----------------
Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma

Conditions
-----------------
Head and Neck Squamous Cell Carcinoma (HNSCC)

Intervention / Treatment
-----------------
* Drug: Netopitam Palonosetron capsules and dexamethasone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female, aged 18-75 years old; Head and neck tumors confirmed by histology or cytology (including oral cancer, oropharyngeal cancer, hypopharyngeal cancer, and laryngeal cancer); Receive radical synchronous radiotherapy and chemotherapy; The Eastern Oncology Collaborative Group (ECOG) physical fitness score of the subjects was ≤ 2 points; Adequate organ and bone marrow function; The expected life is at least 12 weeks; Pregnant or fertile patients (male or female) use reliable contraceptive measures; When screening female patients with potential pregnancy, the pregnancy test must be negative; The subjects voluntarily and strictly comply with the requirements of the research protocol and sign a written informed consent form. Exclusion Criteria: Recurrent and metastatic head and neck tumors; Previously underwent tumor resection surgery for treatment; Patients with platinum drug intolerance; Receiving any known or potential antiemetic medication within 24 hours prior to the first day, or experiencing symptoms of vomiting, retching, or mild nausea within 24 hours prior to the first day; Take NK1（neurokinin-1） receptor antagonists or any study medication within 4 weeks before the start of the experiment; Use CYP3A4 inducer within 4 weeks before chemotherapy, and use CYP3A4 substrate or strong or moderate CYP3A4 inhibitor within 1 week; Serious cardiovascular, pulmonary, diabetes, mental and other diseases; Pregnant or lactating women, patients with fertility who are unwilling or unable to take effective contraceptive measures; Drug and/or alcohol abuse; Hypocalcemia or any other condition that may cause vomiting; There are significant factors that affect the absorption of oral medication, such as chronic diarrhea and intestinal obstruction; The subject has allergic reactions to Netopitam Palonosetron capsules or any of their excipients; Within 30 days prior to the baseline visit, the subject participated in another clinical study and used any exploratory drugs or devices; Allow participation in observational research; The researcher determines other situations that may affect the progress of clinical research and the determination of research results.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment Group<br> | Drug: Netopitam Palonosetron capsules and dexamethasone<br>* On the first and third days, they took Netopitam Palonosetron capsules and dexamethasone to reduce the incidence of acute vomiting.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The complete response rate during synchronous radiotherapy and chemotherapy (defined as no vomiting episodes and no emergency medication). |  | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| No significant nausea rate during synchronous radiotherapy and chemotherapy |  | 1 month | 
| Nausea free rate during synchronous radiotherapy and chemotherapy |  | 1 month | 
| No vomiting rate during synchronous radiotherapy and chemotherapy |  | 1 month | 
| The rate of non emergency medication during synchronous radiotherapy and chemotherapy |  | 1 month | 
| The prevalence and severity of oral/oropharyngeal mucositis during synchronous radiotherapy and chemotherapy |  | 1 month | 
| Successful rescue rate of breakthrough vomiting: (defined as no vomiting within 48 hours) |  | 1 month | 
| Evaluate the impact of medication on patients' daily activities of life (evaluated based on the nausea and vomiting questionnaire FLIE) |  | 1 month |